Bertrand J. Jean-Claude, PhD is Director of the CTB Drug Discovery Platform at the Research Institute of the McGill University Health Centre (RI-MUHC) and Associate Leader of the Metabolic Disease and Complications Program (MeDiC). An Associate Professor of Medicine at McGill University, he has received many awards, including the Medical Research Council of Canada (MRC)-Cancer Research Society (CRS) partnered award, the US Department of Defence New Investigator Award and the Fonds de recherche du Québec─Santé (FRQS) Senior Investigator Award. His research program focuses on a novel tumour targeting approach initiated in his Cancer Drug Research Laboratory, termed “the Combi-Targeting concept.” This approach seeks to confer signaling inhibitory properties to potent DNA damaging agents with the purpose of interfering with mechanisms that lead to apoptosis. The first proof-of-concept synthesis of a novel molecule capable of targeting the epidermal growth factor receptor (EGFR) and damaging DNA made Dr. Jean-Claude a pioneer in the rational design of dual targeted kinase inhibitors. He is currently applying the new combi-targeting approach to immune-oncology. In addition to directing a research laboratory and a technological platform, Dr. Jean-Claude leads two major training programs at McGill University: the Graduate Diploma in Clinical Research and the Drug Development Training Program (DDTP).